Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Report Overview
2023
Base Year
2017-2023
Historical Year
2024-2032
Forecast Year
Global Gemcitabine HCL Market Outlook
The global Gemcitabine HCl market reached a value of USD 719.26 million in 2023, driven by the increasing prevalence of cancer across the globe. The market size is anticipated to grow at a CAGR of 7.4% during the forecast period of 2024-2032 to achieve a value of USD 1,367.49 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Segmentation
Gemcitabine HCL can be used alone or with a combination of other drugs to treat cancers like breast cancer, non-small cell lung cancer, ovarian cancer, and pancreatic cancer.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global gemcitabine HCL market can be segmented based on types, applications, end-uses, and regions.
Based on its types, the industry can be categorised as branded and generic.
Based on its application, the gemcitabine HCL market can be segmented into:
- Pancreatic Cancer
- Breast Cancer
- Ovarian Cancer
- Non-Small-Cell Lung Carcinoma (NSCLC)
- Others
Based on its end-uses, the industry can be segmented as hospitals and cancer centres, among others.
The EMR report looks into the regional gemcitabine HCL markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Market Analysis
This increase in the number of cancer cases, along with the rising geriatric population and the associated risk factors, is driving the industry for gemcitabine HCL. Further, with the rise in the number of governmental and healthcare patient support organisations and agencies, which are spreading awareness regarding cancer, the industry is expected to receive a further boost. Technical advancements in the production of generic drugs have led to an increase in the demand for gemcitabine HCl, which is expected to propel the global gemcitabine HCl market over the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
The report presents a detailed analysis of the following key players in the global gemcitabine HCL market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Eli Lilly and Company (NYSE: LLY)
- Teva Pharmaceutical Industries Ltd.
- Accord Healthcare Ltd.
- Pfizer, Inc.
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- Fresenius Kabi AG
- Dr. Reddy’s Laboratories Ltd.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Indications |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Key Questions Answered in the Report
The global market for gemcitabine HCL reached a value of over USD 719.26 million in 2023.
Over the forecast period of 2024-2032, the market is anticipated to grow at a CAGR of 7.4% to reach USD 1,367.49 million by 2032.
The major drivers of the industry, such as the growing prevalence of cancer and other diseases, rising disposable incomes, increasing population, growing demand for generic drugs, increased government initiatives to create health awareness, growing geriatric population, and rapid advancement in the field of medicine and science, are expected to aid the market growth.
The key market trends guiding the growth of the market include the growing investment in the research and development of drugs and growth in the number of clinical trials being conducted across the globe.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Branded and generic are the major gemcitabine HCL types in the industry.
The significant applications of the product are pancreatic cancer, breast cancer, ovarian cancer, and non-small-cell lung carcinoma (NSCLC), among others.
Hospitals and cancer centres, among others, are the major end use sectors of the product.
The major players in the industry are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, and Dr. Reddy’s Laboratories Ltd., among others.
Purchase Full Report
Datasheet
- Selected Sections, One User
- Printing Not Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Single User License
One User
- All Sections, One User
- One Print Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
Five Users
- All Sections, Five Users
- Five Prints Allowed
- Email Delivery in PDF
- Free Limited Customisation
- Post Sales Analyst Support
50% Discount on Next Update
Corporate License
Unlimited Users
- All Sections, Unlimited Users
- Unlimited Prints Allowed
- Email Delivery in PDF + Excel
- Free Limited Customisation
- Post Sales Analyst Support
- 50% Discount on Next Update
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Our Offices
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124